Results 201 to 210 of about 35,888 (296)

Circulating plasma protein biomarkers associated with risk of negative clinical outcomes in virally suppressed people with HIV receiving medications for opioid use disorder. [PDF]

Front Mol Biosci
Azzoni L, Zhang L, Zhu K, Fair M, Hiserodt E, Mounzer K, Wallin JJ, Montaner LJ, Cai Y.   +8 more
europepmc   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Access to Medications for Opioid Use Disorder Among Veterans With Homeless Experience in Permanent Supportive Housing.

JAMA Netw Open
Hsu M, Panadero T, Mooney LJ, Kim D, Lawrence D, Yuan A, Siddarth P, Gabrielian S.   +7 more
europepmc   +1 more source

Access to medications for opioid use disorder among primary care patients with homeless experience in the Department of Veterans Affairs. [PDF]

Drug Alcohol Depend
Jones AL, Li H, Baylis JD, Huebler S, Suo Y, Zhang Y, Gelberg L, Zickmund S, Greene TH, Kertesz SG, Gordon AJ.   +10 more
europepmc   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source

The Financial Sustainability of Programs to Initiate Medications for Opioid Use Disorder in Emergency Department Settings. [PDF]

Acad Emerg Med
Hodgkin D, Thomas CP, Davis MT, Wicks JJ, Greenfield SF, Meisel ZF, Horgan CM.   +6 more
europepmc   +1 more source

What anabolic–androgenic steroids reveal about the limits of current harm reduction models

Addiction, EarlyView.
Abstract Background Harm reduction has largely been shaped by responses to psychoactive drug use where the most urgent harms are acute. These models focus on overdose, blood‐borne viruses, and rapid‐onset toxicity related harms. When applied wholesale to anabolic–androgenic steroids (AAS), they obscure the distinctive pharmacology, consumer typologies,
Timothy Piatkowski, Jason M. Nagata, Suzanne Nielsen   +2 more
wiley   +1 more source

Three trajectories of implementation of medications for opioid use disorder in primary care. [PDF]

Addict Sci Clin Pract
Kepner W, Vest N, Risner E, Cheng H, Hurley B, Snyder H, McGovern M.   +6 more
europepmc   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Medicaid prescription cap policies and exemptions for medications for opioid use disorder: A process and content analysis. [PDF]

Health Aff Sch
Hughto JMW, Vento S, Pletta DR, Noh M, Shireman TI, Santostefano CM, Hughes LD, Peterson L, Seymour E, Stettenbauer EG, Dow PM.   +10 more
europepmc   +1 more source